Stories, trends, deal makers and breakers, investors and seekers. Read about PE investment deals, M&A, capital markets and business in general, right here!

global_healthcare_deals_private_equity

Innovation across healthcare – be it medical devices, clinical research, or medicine, is advancing rapidly. Businesses globally, are seeing the value in making a move to consolidate their position within the sector, and moving fast to claim a piece of…

Innovation across healthcare – be it medical devices, clinical research, or medicine, is advancing rapidly. Businesses globally, are seeing the value in making a move to consolidate their position within the sector, and moving fast to claim a piece of the pie. Here are some of the private equity deals, offers, and acquisitions that have occurred in the past few weeks.

US-based Boston Scientific Corporation acquired Swiss company, Symetis SA

Boston Scientific Corporation announced its acquisition of privately held structural heart company, Symetis SA for $435 million. This move to acquire Symetis closely followed its acquisition of the manufacturing assets of Neovasc, Inc. Boston Scientific has continued to invest in structural heart through intellectual property, R&D, and manufacturing capabilities, and these strategic acquisitions are enabling the company to consolidate its position in structural heart globally.

MedPlast Inc. acquired Vention Medical’s device manufacturing services business

 MedPlast Inc., a services provider to the medical device industry, acquired Vention Medical’s device manufacturing services business. The acquisition would enable MedPlast to diversify its manufacturing capabilities and will also strengthen its position as a leading services provider to the world’s largest original equipment manufacturers. MedPlast Inc. is backed by JLL Partners and Water Street Healthcare Partners.

China’s Creat Group Corp offered to buy German company Biotest

Chinese investor, Creat Group Corp, offered to buy German blood plasma products maker, Biotest, for close to 1.2 billion euros ($1.3 billion USD) including debt, according to a Reuters report. Biotest, whose products are used to treat blood coagulation disorders, auto-immune diseases and immune deficiencies, shared that the potential deal would be subject to final negotiations and an agreement with its majority shareholder, OGEL.

Genstar Capital acquired Bracket from Parthenon Capital Partners

Middle-market private equity firm, Genstar Capital, announced its acquisition of Bracket, a scientifically-driven clinical trial technology and specialty services provider, from Parthenon Capital Partners.

Genstar Capital is a PE firm which focuses on investments in targeted segments of healthcare and other industries. Bracket offers an integrated suite of solutions that help pharmaceutical and biotechnology companies maximize clinical data integrity.

 Image source: Pixabay

Comments